biotech deals

Glowing puzzle piece fitting into puzzle
Biotech

Biogen pens $1B deal for Vanqua's preclinical C5aR1 antagonist

Biogen plans to beef up its early-stage immunology pipeline by handing over $70 million for the rights to Vanqua Bio’s preclinical C5aR1 antagonist.
James Waldron Oct 24, 2025 9:15am
Illustration connected puzzle pieces with the acronym MA

Ipsen inks €1B buyout of French biotech ImCheck

Oct 22, 2025 10:33am
piggy bank surrounded by question marks

PE dealmaking, exit counts on the rise in Q3: PitchBook

Oct 20, 2025 5:05pm
Heat red cracked ground texture burning after volcano eruption Molten active lava texture background

Xoma and Lava buyout cools with lower offer

Oct 17, 2025 2:35pm
Silhouette of Businessman Entering Lit Door Passage in Darkness

Astellas turns down option to license Taysha gene therapy—again

Oct 17, 2025 10:50am
kite

Kite puts $1.64B on the line for Pregene's in vivo CAR-Ts

Oct 16, 2025 4:56pm